The Lancet 'Under Review': What Each Status Means and When to Expect a Decision

The durations in this table and in the day-range sections below are our unofficial estimates. The Lancet publishes no status-by-status timeline.

Before the paper reaches external reviewers, The Lancet's in-house editorial team evaluates whether the global-clinical-impact warrants the Lancet's selective editorial slots. A high proportion of submissions are rejected at this stage, and the journal says that decision is communicated quickly. A desk rejection most often means the in-house team concluded that the work would fit better at a sister Lancet journal (Lancet Public Health, Lancet Infectious Diseases, Lancet Oncology, Lancet Neurology, EClinicalMedicine for open-access cascade) or that the global-clinical-impact bar is not met.

At The Lancet, administrative processing is not just a file-count check. For a clinical trial or cohort paper, the intake package should let the editor connect the title page, structured abstract, protocol or trial registration, CONSORT or STROBE checklist, ethics approval, conflict-of-interest declaration, data-sharing statement, and supplementary methods without hunting across disconnected files. A weak intake package can make a strong clinical question look less mature before the in-house assessment begins.

The senior editor reads the paper and evaluates global-clinical-impact, scientific rigor, and Lancet family routing. The in-house editorial team meets regularly to discuss ambiguous-fit submissions. The Lancet's in-house team includes senior editors with clinical-research backgrounds; complex papers may be co-evaluated by two editors.

In parallel with the senior editor's primary read, ambiguous-fit papers are discussed at the Lancet editorial team meeting where peer senior editors weigh in on whether the paper would fit better at The Lancet, a Lancet specialty journal (Lancet Oncology, Lancet Public Health, etc.), or EClinicalMedicine. This editorial-team discussion runs alongside the desk-screen and adds 3 to 5 days to the timeline that is invisible to the author in the portal.

Lancet senior editors typically recruit four reviewers per research article (three clinical or subject-based experts plus one statistical reviewer), per Lancet's published peer-review policy. The recruitment window can take 7 to 14 days because reviewers with topic-matched global-clinical-impact expertise are scarce.

Once reviewers agree to review, the typical Lancet peer-review cycle lasts 2 to 6 weeks per reviewer. The Lancet's concurrent statistical review and clinical scrutiny mean the process is thorough, not rushed. Reviewers are asked to evaluate global-clinical-impact, scientific rigor, statistical methodology, and reproducibility. Reviewer reports for The Lancet tend to be thorough given the high-stakes editorial decision.

After reports return, Lancet editors meet to review the comments and decide whether to take the manuscript forward. Once peer reviewer comments are submitted (usually three, plus the statistical review), Lancet editors meet to review the comments and decide whether to take the manuscript forward. By our estimate, even papers that reach review face a ~40 to 50 percent rejection rate at that stage.

• Rejection within 1 to 5 days: Administrative issue or immediate scope mismatch.

• Rejection within 1 to 2 weeks: In-house editorial team desk rejection, which the Lancet says affects a high proportion of submissions.

• Still Under Review after 3 weeks: Strong signal. Paper passed the in-house assessment.

• Still Under Review after 10 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the Editorial Manager portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks after senior editorial team meeting.

This is the most common anxiety we hear from Lancet authors during the active editorial window. The honest answer: no, 6 weeks at Under Review puts you in the normal middle of The Lancet's 4 to 8 week post-screen peer-review distribution. Reports may already be in editorial synthesis with the senior editors preparing to meet to review the comments.

Most reviewer-driven delays come from reviewer-recruitment timing rather than slow reviews because The Lancet recruits topic-matched global-clinical-impact reviewers plus statistical reviewers, and the 3+ reviewer model takes longer to recruit than the 2-reviewer norm at many specialty journals.

If the portal still says Under Review at the 9-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension or that the statistical reviewer is still completing the concurrent review. This is normal practice at The Lancet.

At 6 weeks, the better use of time is to audit the statistical-analysis plan, CONSORT flow diagram, endpoint hierarchy, missing-data language, and data-sharing statement against the clinical claim in the abstract. Those are the manuscript components most likely to decide whether a favorable specialist review becomes a revision invitation rather than a post-review rejection.

If your Lancet paper is rejected after review, the natural cascade depends on what the reviewers and editor cited:

Lancet specialty journals (Lancet Oncology, Lancet Public Health, Lancet Infectious Diseases, Lancet Neurology, etc.) are the natural Lancet cascades where the specialty editorial scope fits. The Lancet Group supports transfers to other Lancet or relevant Elsevier journals, only with author approval, and the original peer review comments may be transferred where relevant.

EClinicalMedicine is the Lancet open-access cascade for clinical-research papers where the open-access publishing model fits.

NEJM is the external general-medicine cascade for top-tier clinical-impact work. NEJM operates independently from The Lancet and uses ScholarOne at ScholarOne submission portal; editorial contact nejm@nejm.org.

JAMA is the AMA general-medicine cascade. JAMA uses ScholarOne at ScholarOne submission portal; editorial contact jama-editor@jamanetwork.org.

BMJ is the British general-medicine open-access cascade.

Reviewers are invited to provide written comments for authors and confidential comments to editors, and are specifically asked to check the content and accuracy of the Research in context panel. In our experience, four focus areas recur. The table below maps each to actionable preparation.

In our pre-submission work with Lancet-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the desk screen.

Narrow-clinical-impact framing flagged at desk screen. When the introduction frames the work too narrowly without global-clinical-impact, in-house team desk rejection is common. The strongest manuscripts frame the title, structured abstract, trial rationale, and first table around a global-clinical-impact question the findings would inform. A Lancet editor should be able to see the clinical decision, health-system consequence, and patient-population relevance before the methods detail begins.

Check whether your Lancet clinical-impact framing is clear →

Statistical methodology gaps surface as concurrent statistical reviewer concerns. When statistical methods documentation is thin (especially sample-size justification, multiple-testing adjustments, missing-data handling, subgroup logic, or sensitivity analyses), the concurrent statistical reviewer consistently flags concerns before clinical peer review proceeds. The strongest revisions include detailed statistical methodology with trial-registration, protocol, statistical-analysis-plan, and data-sharing documentation aligned to the claims in the abstract.

Check your Lancet statistical-review readiness →

Lancet specialty cascade offers from in-house team. When the in-house team concludes the work is rigorous but the global-clinical-impact bar of The Lancet is not met, transfer offers to a Lancet specialty journal (Lancet Oncology, Lancet Public Health, etc.) or EClinicalMedicine are common. Lancet editors take these transfers seriously, and the decision letter often signals whether the abstract, endpoint hierarchy, and discussion can be reframed for a specialty audience or whether the study design itself cannot support the flagship claim.

Check whether your paper fits The Lancet or a Lancet specialty journal →

We have reviewed 50+ manuscripts targeting The Lancet, NEJM, JAMA, BMJ, Annals of Internal Medicine, and Lancet specialty journals. This guide tells you what Lancet editors look for in the status window, while the review tells you whether your paper passes the same global-clinical-impact, statistical-methods, CONSORT, and response-letter checks before in-house editors or external reviewers see it. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

In our pre-submission review work across general-medicine and specialty-clinical targets, Lancet-bound drafts most often failed when the abstract promised practice-changing significance but the endpoint hierarchy, statistical-analysis plan, or patient-population rationale did not make that significance defensible. We see this as a recurring failure pattern because the in-house editorial team can separate global clinical relevance from single-system specialty interest before external review.

Source limitation: official guidance explains The Lancet's editorial path and reviewer model, but it cannot diagnose whether your specific trial, cohort, or systematic review has enough global-clinical consequence for The Lancet rather than a specialty Lancet title.

This page was created from The Lancet's public editorial policies at Thelancet editorial team page, Lancet Journey of a Paper documentation (a high proportion rejected on in-house assessment alone, usually 3 peer reviewers plus a statistical reviewer), SciRev community data (12 author reports: first review round averaging 2.0 months, immediate rejections at about 18 days), and Manusights pre-submission review experience with Lancet-targeted manuscripts.

For the general-medicine landscape beyond The Lancet, see Lancet specialty journals (Lancet Oncology, Lancet Public Health, Lancet Infectious Diseases, Lancet Neurology for specialty editorial scope), EClinicalMedicine (Lancet open-access cascade), and external general-medicine alternatives (NEJM, JAMA, BMJ, Annals of Internal Medicine).

The choice across these titles depends on whether the central contribution is top-tier global-clinical-impact (The Lancet), specialty Lancet scope (specialty journals), Lancet open-access clinical-research (EClinicalMedicine), top-tier evidence-changes-practice (NEJM), AMA general-medicine (JAMA), British open-access general-medicine (BMJ), or internal-medicine clinical-research (Annals of Internal Medicine).

Reviewers at The Lancet typically draw from 3 clinical specialists plus a statistical reviewer. Editors screen and triage manuscripts before any external reviewer sees them, with the concurrent statistical review providing an additional layer of methodology evaluation. Preparing a response template that addresses global-clinical-impact, statistical methodology, and CONSORT compliance accelerates revision rounds substantially.

If the decision comes back as a major revision, read our guide on what a Lancet major revision means before you start on the statistical reviewer's points.

For a pre-upload check of your manuscript against the Lancet global-clinical-impact-plus-statistical-rigor bar before submission, our Lancet pre-submission diagnostic flags the framing and CONSORT-compliance weaknesses most likely to surface in reviewer reports.